October 21, 2021 10:49 AM EDTUpdated 02:02 PM

Teva appeals to court to keep 'incredibly damaging' Hollywood parody videos under wraps in New York opioid case

Beth Snyder Bulik

Senior Editor

Teva is doubling down to prevent “parody” marketing videos from entering the courtroom in its New York opioid trial. The 15-year-old Cephalon videos connected to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Teva appeals to court to keep 'incredibly damaging' Hollywood parody videos under wraps in New York opioid case

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Applied Therapeutics' rare disease drug gets a CRL

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Te­va ap­peals to court to keep 'in­cred­i­bly dam­ag­ing' Hol­ly­wood par­o­dy videos un­der wraps in New York opi­oid case

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Teva appeals to court to keep 'incredibly damaging' Hollywood parody videos under wraps in New York opioid case

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Applied Therapeutics' rare disease drug gets a CRL

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks